Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $71.50 short call and a strike $76.50 long call offers a potential 27.55% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $71.50 by expiration. The full premium credit of $1.08 would be kept by the premium seller. The risk of $3.92 would be incurred if the stock rose above the $76.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is at 36.35 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Edited Transcript of GILD earnings conference call or presentation 25-Oct-18 8:30pm GMT
Tue, 30 Oct 2018 02:04:44 +0000
Q3 2018 Gilead Sciences Inc Earnings Call
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Mon, 29 Oct 2018 21:45:09 +0000
In the latest trading session, Gilead Sciences (GILD) closed at $70.90, marking a +1.66% move from the previous day.
Gilead charged $1,100 a day for this drug. Now it will launch a generic at quarter the price.
Mon, 29 Oct 2018 20:53:33 +0000
The Foster City-based company said its generic versions of Harvoni, as well as Epclusa, will increase its market and reduce patient out-of-pocket expenses.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
Mon, 29 Oct 2018 17:44:05 +0000
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
7 Rising Healthcare Stocks to Consider
Mon, 29 Oct 2018 16:09:13 +0000
The recovery in healthcare stocks started in May 2018 but faced some selling pressure in recent weeks as market volatility increased. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) fell by around 4.3% in the last week, and is down slightly on the year.
Also on Market Tamer…
Follow Us on Facebook